|Videos|July 14, 2022
A Cross-Sectional Survey Reveals Physicians’ Treatment Patterns in First-Line and Maintenance Therapy for la/mUC
Author(s)Shilpa Gupta, MD, Vinit Makkar, MD
Drs Gupta and Makkar discuss results from the PARADIGM cross-sectional survey, which reveals physicians’ 1L and 1LM treatment patterns in la/mUC.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Patient-Centered Treatment Transitions in HR+/HER2− mBC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5